Herniorrhaphy Study for Opioid Elimination

NCT ID: NCT03907176

Last Updated: 2022-02-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

115 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-05

Study Completion Date

2021-11-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 3b, open-label study to assess postoperative opioid use in subjects undergoing unilateral open inguinal herniorrhaphy with intraoperative administration of HTX-011 and a postoperative non-opioid multimodal analgesic (MMA) regimen. The study will be conducted in 2 sequential parts: Part 1 is randomized and Part 2 is Investigator's preference for MMA regimen.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Analgesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

In Part 1, subjects who meet the Screening eligibility criteria (Section 4.1) will be randomized to one of the 2 parallel cohorts. In Part 2, prior to surgery, the Investigator will select for the subject one of the 2 postoperative MMA regimens, based on Investigator and/or subject preference.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

HTX-011; Ibuprofen and Acetaminophen (regimen 1)

Group Type EXPERIMENTAL

HTX-011

Intervention Type DRUG

300 mg

Luer lock applicator

Intervention Type DEVICE

Applicator for instillation

Ibuprofen

Intervention Type DRUG

600 mg

Acetaminophen

Intervention Type DRUG

1 g

Cohort 2

HTX-011; Ibuprofen and Acetaminophen (regimen 2)

Group Type EXPERIMENTAL

HTX-011

Intervention Type DRUG

300 mg

Luer lock applicator

Intervention Type DEVICE

Applicator for instillation

Ibuprofen

Intervention Type DRUG

600 mg

Acetaminophen

Intervention Type DRUG

1 g

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HTX-011

300 mg

Intervention Type DRUG

Luer lock applicator

Applicator for instillation

Intervention Type DEVICE

Ibuprofen

600 mg

Intervention Type DRUG

Acetaminophen

1 g

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is scheduled and medically fit to undergo an elective unilateral open inguinal herniorrhaphy with mesh under deep sedation or general anesthesia; no neuraxial technique (eg, no spinal or epidural).
* Has an American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.
* Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.

Exclusion Criteria

* Has a planned concurrent surgical procedure (eg, bilateral herniorrhaphy).
* Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
* Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
* Part 1 only: Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months. Part 2 only: Has known or suspected history of persistent opioid use, defined as daily, or almost daily, use of opioids for a period of at least 30 days within the previous 6 months.
* Has taken any opioids within 24 hours prior to the scheduled surgery.
* Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
* Has uncontrolled anxiety, psychiatric, or neurological disorder.
* Has a known or suspected history of drug abuse, has a positive drug screen on the day of surgery, consumes 3 or more alcoholic drinks every day, or has a recent history of alcohol abuse.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Heron Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Anaheim Clinical Trials, LLC

Anaheim, California, United States

Site Status

Horizon Clinical Research

La Mesa, California, United States

Site Status

Sharp Grossmont Hospital

La Mesa, California, United States

Site Status

University of California, Irvine Medical Center

Orange, California, United States

Site Status

Parkview Community Hospital

Riverside, California, United States

Site Status

Yale University School of Medicine

New Haven, Connecticut, United States

Site Status

Medical Research of Westchester, Inc

Miami, Florida, United States

Site Status

Professional Health Care of Pinellas

St. Petersburg, Florida, United States

Site Status

University of Louisville Hospital

Louisville, Kentucky, United States

Site Status

Baylor University Medical Center

Dallas, Missouri, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Rutgers - New Jersey Medical School

Newark, New Jersey, United States

Site Status

Stony Brook University Hospital

Stony Brook, New York, United States

Site Status

Montefiore Hutchinson Campus

The Bronx, New York, United States

Site Status

M3 Emerging Medical Research, LLC

Durham, North Carolina, United States

Site Status

Cleveland Clinic Fairview

Cleveland, Ohio, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

The Ohio State University Wexner Medical Center - University Hospital

Columbus, Ohio, United States

Site Status

Midwest Clinical Research Center, LLC

Dayton, Ohio, United States

Site Status

Summit Medical Group Oregon-Bend Memorial Clinic

Bend, Oregon, United States

Site Status

Penn Presbyterian Medical Center

Philadelphia, Pennsylvania, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

UPMC Shadyside Hospital

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Passavant

Pittsburgh, Pennsylvania, United States

Site Status

Baylor University Medical Center

Dallas, Texas, United States

Site Status

Hermann Drive Surgical Hospital

Houston, Texas, United States

Site Status

Houston Methodist Hospital

Houston, Texas, United States

Site Status

Plano Surgical Hospital

Plano, Texas, United States

Site Status

Endeavor Clinical Trials, LLC

San Antonio, Texas, United States

Site Status

JBR Clinical Research

Draper, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HTX-011-304

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Chloroprocaine for Inguinal Herniorrhaphy
NCT03805503 COMPLETED PHASE4